| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJM198001033020106 |
| P698 | PubMed publication ID | 7350395 |
| P2093 | author name string | O'Reilly RA | |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | (RS)-warfarin | Q407431 |
| stereoselectivity | Q903429 | ||
| P304 | page(s) | 33-35 | |
| P577 | publication date | 1980-01-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Stereoselective interaction of trimethoprim-sulfamethoxazole with the separated enantiomorphs of racemic warfarin in man | |
| P478 | volume | 302 |
| Q34196283 | American Heart Association/American College of Cardiology Foundation guide to warfarin therapy |
| Q42877020 | Antithrombotic Activity of the Novel Oral Anticoagulant, Tecarfarin [Sodium 3-[4-((1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yloxy) carbonyl) benzyl]-2-oxo-2H-chromen-4-olate] in Animal Models |
| Q37193023 | Benefit-risk assessment of telithromycin in the treatment of community-acquired pneumonia |
| Q42116398 | Cimetidine-nicoumalone interaction in man: stereochemical considerations |
| Q38631282 | Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy |
| Q71295310 | Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole) |
| Q34734558 | Clinically important drug interactions with anticoagulants. An update |
| Q34268594 | Co-trimoxazole (trimethoprim-sulfamethoxazole): an updated review of its antibacterial activity and clinical efficacy. |
| Q34223201 | Considerations when prescribing trimethoprim-sulfamethoxazole |
| Q34446735 | Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition |
| Q70268807 | Drug interactions with warfarin |
| Q33858325 | Effects of the antifungal agents on oxidative drug metabolism: clinical relevance |
| Q36330247 | Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics |
| Q39834900 | Importance of drug enantiomers in clinical pharmacology |
| Q70426614 | Interaction of sulphinpyrazone with warfarin |
| Q35161650 | Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin |
| Q37544345 | Molecular asymmetry and its pharmacological consequences |
| Q40076893 | On chiral drug action |
| Q34252907 | Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
| Q34196128 | Oral anticoagulants. Pharmacologic issues for use in the elderly |
| Q40720380 | Pharmacokinetic drug interactions with antimicrobial agents |
| Q40905445 | Pharmacokinetic optimisation of the treatment of deep vein thrombosis |
| Q40753816 | Plasma protein binding displacement interactions--why are they still regarded as clinically important? |
| Q40151099 | Protein binding displacement interactions and their clinical importance |
| Q42073220 | Stereoselective interaction between the R enantiomer of warfarin and cimetidine |
| Q70451297 | The effect of cotrimoxazole on oral contraceptive steroids in women |
| Q70426611 | The effect of sulphinpyrazone on oxidative drug metabolism in man: inhibition of tolbutamide elimination |
Search more.